Jonathon P. Orme
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, Tuberculosis Research and Epidemiology, HER2/EGFR in Cancer Research, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer(2014)2,182 cited
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)(2013)258 cited
- → Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase(2012)46 cited
- → Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro(1992)36 cited
- → Selective inhibition of protein secretion by abrogating receptor–coat interactions during ER export(2022)30 cited
- → Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.(2013)19 cited
- → Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors(2015)11 cited
- → Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.(2017)8 cited
- → K+ -Channel blockers and coronary vasoconstriction in guinea-pig perfused hearts in-vitro(1993)3 cited